| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
IC50: 3.11 μM (A/Puerto Rico/8/34 (H1N1)), 3.58 μM (A/FM-1/1/47 (H1N1)), 5.26 μM (A/Aichi/2/68 (H3N2)), 6.48 μM (A/PR/8/34 (H1N1) with NA-H274Y) and 7.13 μM (The influenza A virus 690 (H3))
Influenza A virus, specifically viral replication and protein expression. The compound targets the influenza A virus replication cycle, interfering with viral protein function and disrupting critical steps in viral RNA synthesis. It also modulates host antiviral responses by upregulating IFN-beta and MxA expression. |
|---|---|
| ln Vitro |
Treatment of influenza A virus-IN-1 (compound 5-2; 5–40 μM; 24 hours; MDCK cells) dramatically reduces, in a dose-dependent manner, the yields of influenza viral NP. Furthermore, there may be a dose-dependent limitation on the amount of NP protein expression[1]. At all three time points, influenza HA mRNA expression is decreased by influenza A virus-IN-1 (compound 5-2) treatment[1]. In MDCK cells, influenza A virus-IN-1 (compound 5-2) has the ability to effectively block IAV replication and reduce the synthesis of NDAPH oxidase NOX1[1].
Influenza A virus-IN-1 has IC₅0 values of 3.11 microM against A/Puerto Rico/8/34 (H1N1), 3.58 microM against A/FM-1/1/47 (H1N1), 5.26 microM against A/Aichi/2/68 (H3N2), and 6.48 microM against A/PR/8/34 (H1N1) with NA-H274Y. Treatment at 5-40 microM for 24 hours dramatically reduces influenza viral NP yields in a dose-dependent manner and decreases influenza HA mRNA expression. The compound effectively blocks IAV replication and reduces NADPH oxidase NOX1 synthesis in MDCK cells. |
| ln Vivo |
No detailed in vivo activity data has been reported for Influenza A virus-IN-1. As a potent IAV inhibitor with favorable in vitro activity, it could potentially be evaluated in mouse models of influenza infection, with efficacy assessed by viral load reduction, symptom improvement, and survival.
|
| Enzyme Assay |
Influenza A virus-IN-1 is tested in enzyme-based or cell-based antiviral assays. Viral replication is measured by plaque reduction assays, qPCR for viral RNA, or immunofluorescence for viral proteins (e.g., NP). IC₅0 values are calculated from dose-response curves against various IAV strains.
|
| Cell Assay |
Western Blot Analysis[1]
Cell Types: IAV-infected MDCK cells Tested Concentrations: 5 μM, 10 μM, 20 μM, 40 μM Incubation Duration: 24 hrs (hours) Experimental Results: Dramatically diminished the yields of influenza viral NP in a dose-dependent manner. MDCK cells are infected with influenza A virus and treated with serial dilutions of Influenza A virus-IN-1 (5-40 microM) for 24 hours. Viral NP protein expression is measured by Western blot or immunofluorescence. Viral HA mRNA expression is measured by qPCR. Cell viability is assessed using standard cytotoxicity assays. |
| Animal Protocol |
Animal models of influenza infection (e.g., mouse models infected with IAV strains such as H1N1 or H3N2) could be used. Influenza A virus-IN-1 would be administered orally or intraperitoneally, and efficacy would be assessed by viral load, survival, weight loss, and lung pathology.
|
| ADME/Pharmacokinetics |
Influenza A virus-IN-1 has a molecular weight of 534.45 and a molecular formula of C2₇H20F₆N2O3. It is a dihydropyrrolidone analogue with a purity of ≥98%. It is soluble in DMSO. Detailed pharmacokinetic parameters have not been reported.
|
| Toxicity/Toxicokinetics |
No toxicity data has been published for Influenza A virus-IN-1. As a research compound, it is not intended for human therapeutic use. Cell-based assays indicate that the compound is tolerated at the tested concentrations in MDCK cells.
|
| References | |
| Additional Infomation |
Influenza A virus-IN-1 is a dihydropyrrolidone derivative and a potent inhibitor against a wide range of influenza A virus subtypes with IC₅0 values of 3.11-7.13 microM. It inhibits IAV replication and upregulates IFN-beta and MxA expression. The compound is for research use only and has not entered clinical trials.
|
| Molecular Formula |
C27H20F6N2O3
|
|---|---|
| Molecular Weight |
534.45
|
| Exact Mass |
534.137
|
| CAS # |
2250313-14-3
|
| PubChem CID |
141537169
|
| Appearance |
White to off-white solid powder
|
| LogP |
7.1
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
10
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
38
|
| Complexity |
880
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C(=O)(C1=C(NC2C=CC(=CC=2)C(F)(F)F)C(=O)N(C2C=CC(C(F)(F)F)=CC=2)C1C1=CC=CC=C1)OCC
|
| InChi Key |
IRTZGBURXBOHPW-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C27H20F6N2O3/c1-2-38-25(37)21-22(34-19-12-8-17(9-13-19)26(28,29)30)24(36)35(23(21)16-6-4-3-5-7-16)20-14-10-18(11-15-20)27(31,32)33/h3-15,23,34H,2H2,1H3
|
| Chemical Name |
ethyl 5-oxo-2-phenyl-4-[4-(trifluoromethyl)anilino]-1-[4-(trifluoromethyl)phenyl]-2H-pyrrole-3-carboxylate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~187.11 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.8711 mL | 9.3554 mL | 18.7108 mL | |
| 5 mM | 0.3742 mL | 1.8711 mL | 3.7422 mL | |
| 10 mM | 0.1871 mL | 0.9355 mL | 1.8711 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
